Here are the latest stories being discussed in biopharma today:

U.S. Senator Bernie Sanders is pushing global pharmaceutical leaders to support the WHO’s Pandemic Accord proposals, urging them to ensure that treatments are accessible worldwide.

Bristol Myers Squibb is set to close its cell therapy manufacturing site in Redwood City, California. The closure, part of a $1.5 billion cost-cutting program, will see some employees relocated to another site in Brisbane, whereas others will be let go.

Cigna’s health services arm Evernorth plans to offer a cheaper biosimilar of AbbVie’s Humira for $0. However, this move is unlikely to significantly increase the use of biosimilars as brand-name drugs continue to dominate the market.

The FDA has approved a label update for Gilead’s HIV drug Biktarvy to include more data on the drug’s safety and efficacy for people who are pregnant.

Biopharmaceutical company Ipsen has sponsored a popular TikTok trend to help explain the symptoms of fibrodysplasia ossificans progressiva (FOP), a rare disease that causes bone formation in soft and connective tissues.

The European Medicines Agency’s human medicines committee (CHMP) has recommended the approval of eight new drugs, and six new label expansions.

Lastly, AbbVie has surpassed first-quarter expectations, but its guidance for the future of Humira leaves analysts confused.